459P - Association between national health screening program and undertreatment of dyslipidemia in cancer survivors: A cross-sectional study

Background

With cancer as the leading cause of death in Korea and globally, addressing non-cancer mortality, specifically cardiovascular disease, is critical. Dyslipidemia, a significant risk factor for cardiovascular disease, requires proper management in cancer survivors. This study aims to analyze factors associated with undertreatment of dyslipidemia in cancer survivors and investigate the impact of the National Health Screening Program (NHSP) on undertreatment in Korea.

Methods

This cross-sectional study analyzed data from the Korea National Health and Nutrition Survey (KNHANES) conducted between 2007 and 2019. It included 2,226 participants (792 males, 1,434 females) aged 40-75 who had a history of cancer. Self-reported questionnaires collected information following the 2018 Cholesterol Treatment Guidelines by the American College of Cardiology/American Heart Association. Multiple logistic regression analysis with integrated weights was performed.

Results

Among cancer survivors, 16.3% received treatment for dyslipidemia. Of those who were untreated, 46.64% had normal blood lipid levels, while 37.0% were not receiving adequate treatment. Additionally, 72.7% of cancer survivors participated in the NHSP, and the undertreatment rate for dyslipidemia was significantly lower in the screened group compared to the non-screened group (34.14% vs. 44.78%; P < 0.001). Adjusting for age and sex, cancer survivors in the non-screened group had a significantly higher risk of not receiving appropriate dyslipidemia treatment (odds ratio [OR] 1.47, 95% confidence interval [CI] 1.10, 1.97). Even after considering socioeconomic and cancer-related factors, the non-screened group remained significantly associated with undertreatment of dyslipidemia (OR 1.36, 95% CI: 1.02, 1.82), especially among female cancer survivors (OR 1.49, 95% CI: 1.05, 2.14).

Conclusions

This study is the first to assess the association between NHSP and undertreatment of dyslipidemia. Encouraging cancer survivors to participate in the NHSP would be an effective strategy to reduce the incidence and mortality of concurrent cardiovascular disease, ultimately improving the overall health of cancer survivors.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.